MIRA INFORM REPORT
|
Report Date : |
14.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
PHIL. PHARMAWEALTH, INC. |
|
|
|
|
Registered Office : |
Suite 3001, 30th Floor, East Tower, Phil. Stock Exchange
Center, Exchange Road, Ortigas Center 1605, Pasig City |
|
|
|
|
Country : |
Philippines |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
10.02.1993 |
|
|
|
|
Com. Reg. No.: |
AS093-01037 |
|
|
|
|
Legal Form : |
Corporation |
|
|
|
|
Line of Business : |
Importation & Distribution of finished Pharmaceutical products and
medical supplies. |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRAs Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Philippines |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
PHILIPPINES - ECONOMIC
OVERVIEW
Philippine GDP growth, which cooled from 7.6% in 2010 to
3.9% in 2011, expanded to 6.6% in 2012 - meeting the government's targeted
6%-7% growth range. The 2012 expansion partly reflected a rebound from
depressed 2011 export and public sector spending levels. The economy has
weathered global economic and financial downturns better than its regional
peers due to minimal exposure to troubled international securities, lower
dependence on exports, relatively resilient domestic consumption, large
remittances from four- to five-million overseas Filipino workers, and a rapidly
expanding business process outsourcing industry. The current account balance
had recorded consecutive surpluses since 2003; international reserves are at record
highs; the banking system is stable; and the stock market was Asia's second
best-performer in 2012. Efforts to improve tax administration and expenditure
management have helped ease the Philippines' tight fiscal situation and reduce
high debt levels. The Philippines received several credit rating upgrades on
its sovereign debt in 2012, and has had little difficulty tapping domestic and
international markets to finance its deficits. Achieving a higher growth path
nevertheless remains a pressing challenge. Economic growth in the Philippines
averaged 4.5% during the MACAPAGAL-ARROYO administration but poverty worsened
during her term. Growth has accelerated under the AQUINO government, but with
limited progress thus far in bringing down unemployment, which hovers around
7%, and improving the quality of jobs. Underemployment is nearly 20% and more
than 40% of the employed are estimated to be working in the informal sector.
The AQUINO administration has been working to boost the budgets for education,
health, cash transfers to the poor, and other social spending programs, and is
relying on the private sector to help fund major infrastructure projects under
its Public-Private Partnership program. Long term challenges include reforming
governance and the judicial system, building infrastructure, improving
regulatory predictability, and the ease of doing business, attracting higher
levels of local and foreign investments. The Philippine Constitution and the
other laws continue to restrict foreign ownership in important
activities/sectors (such as land ownership and public utilities).
|
Source
: CIA |
|
Company Name: |
PHIL. PHARMAWEALTH, INC. |
|
Supplied Name: |
PHIL PHARMAWEALTH INC |
|
Trading Address: |
Suite 3001, 30th Floor, East Tower, Phil. Stock
Exchange Center, Exchange Road, Ortigas Center 1605, Pasig City, Philippines |
|
Supplied Address: |
Suite 3001 east tektite Tower, P S E Centre
Exchange Road, Ortigas centre Pasig City Philippines |
|
Telephone Number: |
+632 683-00-53 TO 57 / 634-37-32 / 634-41-82 /
634-35-05 |
|
Fax Number: |
+632 2 6339512 |
|
E-mail: |
Note:
The supplied address is incomplete, and the exact address is as above.
|
Registered Number: |
AS093-01037 |
|
Legal Form: |
Corporation |
|
Date Incorporated: |
|
|
Authorized Capital Stock: |
PHP 50,000,000.00 (USD 1,212,820) (As of 2013.5, 1 PHP =0.02426 USD) |
|
Subscribed Capital Stock: |
PHP 50,000,000.00(USD 1,212,820) |
|
Paid-up Capital: |
PHP 50,000,000.00(USD 1,212,820) |
|
Par Value Per Share: |
PHP 100.00 |
|
Listed at Stock Exchange: |
No |
|
Staff: |
N/A |
Note:
Amounts in Philippine Peso unless otherwise specified.
Information on staff number is not available from subject or other
source.
Company Background
Verification with the local registry revealed the following correct registration
details as of (May 14, 2013).
|
Regulatory Agency |
Date Registered |
Registration No. |
Term |
|
Securities and Exchange Commission |
|
AS093-01037 |
50 Years |
|
Type |
Share |
|
Authorized Capital |
50,000,000.00 |
|
Paid Up |
50,000,000.00 |
|
Subscribed |
50,000,000.00 |
|
Par Value |
100.00 |
Capital structure per latest available General
Information Sheet.
Increase in authorized capital stock from
1,000,000 to 20,000,000 was approved by the Securities and Exchange Commission on
March 26, 1998; then to 50,000,000 on February 18, 1999.
AFFILIATE:
|
Name |
Singapore Pharmawealth Lifesciences, Inc. |
Stockholders: (
|
Name |
Subscribed and Paid Up |
|
ALAMBRA, ALAN A.B. ATTY. |
100.00 |
|
BIRON, HERNAN D. JR. |
100.00 |
|
BIRON, DIANA G. |
24,749,900.00 |
|
BIRON, HERNAN D. SR. |
25,249,800.00 |
|
DEPALAC, JONAS A. |
100.00 |
List of stockholders and their shareholdings per latest available
General Information Sheet.
Management (
|
Name |
Position |
|
BIRON, HERNAN D. SR. |
Chairman |
|
BIRON, DIANA G. |
President / Director |
|
BIRON, HERNAN D. JR. |
Treasurer / Director |
|
PADOJINOG, JULIENNE ROA |
Director |
|
DEPALAC, JONAS A. |
Corporate Secretary / Director |
|
Activities |
|
- Importation & Distribution of finished Pharmaceutical products
and medical supplies. |
|
Premises |
|
Location: Located at the capital address as above. |
Unit: PHP
|
|
|
|
|
Total Current Assets |
176,774,101.00 |
146,334,112.00 |
|
Cash |
7,171,891.00 |
5,442,534.00 |
|
Short Invest |
0.00 |
0.00 |
|
Receivable |
39,761,982.00 |
31,939,845.00 |
|
Inventory |
129,527,714.00 |
106,474,528.00 |
|
Other Current Assets |
312,514.00 |
2,477,205.00 |
|
Long Invest Total |
0.00 |
0.00 |
|
Long Invest Security |
0.00 |
0.00 |
|
Long Invest Equity |
0.00 |
0.00 |
|
Long Invest Other |
0.00 |
0.00 |
|
Fixed Assets Total |
18,856,083.00 |
20,385,918.00 |
|
Fixed Assets |
18,856,083.00 |
20,385,918.00 |
|
Depreciation Total |
0.00 |
0.00 |
|
Intangible Assets |
0.00 |
0.00 |
|
Other Assets |
32,816,000.00 |
32,816,000.00 |
|
Total Assets |
228,446,184.00 |
199,536,030.00 |
|
Total Current Debt |
97,514,097.00 |
69,585,250.00 |
|
Short Loan |
0.00 |
0.00 |
|
Accounts Payable |
38,910,099.00 |
15,870,002.00 |
|
Other Current Liability |
58,603,998.00 |
53,715,248.00 |
|
Long Liability Total |
28,398,567.00 |
30,479,369.00 |
|
Long Leases |
0.00 |
0.00 |
|
Long Loan |
0.00 |
0.00 |
|
Long Loan Other |
0.00 |
0.00 |
|
Total Liability |
125,912,664.00 |
100,064,619.00 |
|
Total Equity |
102,533,520.00 |
99,471,411.00 |
|
Share Capital |
50,000,000.00 |
50,000,000.00 |
|
Capital Paid |
0.00 |
0.00 |
|
Legal Reserve |
0.00 |
0.00 |
|
Surplus Reserve |
0.00 |
0.00 |
|
Undistributed Profit |
0.00 |
0.00 |
|
Retained Earning |
52,533,520.00 |
49,471,411.00 |
|
Other Equity |
0.00 |
0.00 |
|
Total Liability And Equity |
228,446,184.00 |
199,536,030.00 |
Unit: PHP
|
|
2011 |
2010 |
|
Operating Revenue |
0.00 |
0.00 |
|
Sales Revenue |
349,688,573.00 |
374,853,522.00 |
|
Interest Revenue |
0.00 |
0.00 |
|
Other Revenue |
1,233,547.00 |
726,544.00 |
|
Total Revenue |
350,922,120.00 |
375,580,066.00 |
|
Sales Cost |
286,071,537.00 |
306,573,025.00 |
|
Gross Profit |
63,617,036.00 |
68,280,497.00 |
|
Sales Expenses |
0.00 |
0.00 |
|
Management Expenses |
60,476,141.00 |
59,350,601.00 |
|
Financial Expenses |
0.00 |
0.00 |
|
Total Expenses |
346,547,678.00 |
365,923,626.00 |
|
Operating Profit |
4,374,442.00 |
9,656,440.00 |
|
Non Operating Profit |
0.00 |
0.00 |
|
Profit Before Tax |
4,374,442.00 |
9,656,440.00 |
|
Tax |
1,312,333.00 |
2,896,932.00 |
|
Net Profit |
3,062,109.00 |
6,759,508.00 |
Unit: PHP
|
|
2009 |
2008 |
|
Operating Net Cash |
5,065,438.00 |
17,496,353.00 |
|
Investment Net Cash |
-1,255,279.00 |
-1,436,489.00 |
|
Finance Net Cash |
-2,080,802.00 |
11,656,930.00 |
This section contains credit exposure of one million and above transactions
reported quarterly by banks and other financial institutions.
For quarter ending as of December 31, 2012
Subject: PHIL PHARMAWEALTH INC
|
NO |
Collateral/Security |
Co Maker's Name |
Loan Type |
Loan Status |
Outstanding Amount |
Market Gain/Loss |
Secured Amount |
Unsecured Amount |
|
1. |
|
|
Time Loans |
Current |
26,619,744.06 |
0.00 |
0.00 |
26,619,744.06 |
|
2. |
Chattel Mortgage |
|
Time Loans |
Current |
40,134.00 |
0.00 |
39,965.09 |
168.91 |
|
3. |
Chattel Mortgage |
|
Time Loans |
Current |
381,546.00 |
0.00 |
356,362.27 |
25,183.73 |
|
4. |
Chattel Mortgage |
|
Time Loans |
Current |
484,840.00 |
0.00 |
454,383.65 |
30,456.35 |
|
5. |
Chattel Mortgage |
|
Time Loans |
Current |
484,840.00 |
0.00 |
455,919.94 |
28,920.06 |
|
6. |
Chattel Mortgage |
|
Time Loans |
Current |
484,840.00 |
0.00 |
455,919.94 |
28,920.06 |
|
7. |
Chattel Mortgage |
|
Time Loans |
Current |
484,840.00 |
0.00 |
455,919.94 |
28,920.06 |
|
8. |
Chattel Mortgage |
|
Time Loans |
Current |
720,918.00 |
0.00 |
674,308.91 |
46,609.09 |
|
9. |
Chattel Mortgage |
|
Time Loans |
Current |
40,134.00 |
0.00 |
39,965.09 |
168.91 |
|
10. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
1,383,200.00 |
0.00 |
1,383,200.00 |
0.00 |
|
11. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
1,383,200.00 |
0.00 |
1,383,200.00 |
0.00 |
|
12. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
474,630.00 |
0.00 |
425,419.03 |
49,210.97 |
|
13. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
1,349,318.10 |
0.00 |
1,349,318.10 |
0.00 |
|
14. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
878,730.00 |
0.00 |
786,364.03 |
92,365.97 |
|
15. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
1,349,318.10 |
0.00 |
1,349,318.10 |
0.00 |
|
16. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
1,383,200.00 |
0.00 |
1,383,200.00 |
0.00 |
|
17. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
362,592.00 |
0.00 |
332,783.96 |
29,808.04 |
|
18. |
Chattel Mortgage |
BIRON HERNAN D |
Time Loans |
Current |
362,592.00 |
0.00 |
332,783.96 |
29,808.04 |
Loans and Receivables
This section contains credit exposure of one million and above
transactions reported quarterly by banks and other financial institutions. For
quarter ending as of December 31, 2012
Subject: PHILIPPINE PHARMAWEALTH INC
|
NO |
Collateral/Security |
Co Maker's Name |
Loan Type |
Loan Status |
Outstanding Amount |
Market Gain/Loss |
Secured Amount |
Unsecured Amount |
|
1. |
REM - Not Insured by HFC |
|
Time Loans |
Current |
25,000,000.00 |
0.00 |
25,000,000.00 |
0.00 |
|
2. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
257,500.00 |
0.00 |
0.00 |
257,500.00 |
|
3. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
504,989.10 |
0.00 |
0.00 |
504,989.10 |
|
4. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
995,587.20 |
0.00 |
0.00 |
995,587.20 |
|
5. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
380,197.12 |
0.00 |
0.00 |
380,197.12 |
|
6. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
339,200.00 |
0.00 |
0.00 |
339,200.00 |
|
7. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
153,975.30 |
0.00 |
0.00 |
153,975.30 |
|
8. |
REM - Not Insured by HFC |
|
Time Loans |
Current |
20,000,000.00 |
0.00 |
20,000,000.00 |
0.00 |
|
9. |
REM - Not Insured by HFC |
|
Time Loans |
Current |
5,000,000.00 |
0.00 |
5,000,000.00 |
0.00 |
|
10. |
Other Securities |
|
Bills Purchased - Clean |
Current |
1,103,386.70 |
0.00 |
0.00 |
1,103,386.70 |
|
11. |
|
|
32 Lease Contracts Receivable |
Current |
155,262.57 |
0.00 |
0.00 |
155,262.57 |
|
12. |
|
|
32 Lease Contracts Receivable |
Current |
1,226,085.36 |
0.00 |
0.00 |
1,226,085.36 |
|
13. |
|
|
32 Lease Contracts Receivable |
Current |
95,096.98 |
0.00 |
0.00 |
95,096.98 |
|
14. |
|
|
32 Lease Contracts Receivable |
Current |
89,032.18 |
0.00 |
0.00 |
89,032.18 |
|
15. |
|
|
32 Lease Contracts Receivable |
Current |
365,688.18 |
0.00 |
0.00 |
365,688.18 |
|
16. |
|
|
32 Lease Contracts Receivable |
Current |
2,931,844.52 |
0.00 |
0.00 |
2,931,844.52 |
|
17. |
|
|
32 Lease Contracts Receivable |
Current |
120,530.34 |
0.00 |
0.00 |
120,530.34 |
|
18. |
|
|
32 Lease Contracts Receivable |
Current |
138,286.33 |
0.00 |
0.00 |
138,286.33 |
|
19. |
|
|
32 Lease Contracts Receivable |
Current |
27,271.97 |
0.00 |
0.00 |
27,271.97 |
|
20. |
|
|
32 Lease Contracts Receivable |
Current |
1,382,428.93 |
0.00 |
0.00 |
1,382,428.93 |
|
21. |
|
|
32 Lease Contracts Receivable |
Current |
1,115,092.44 |
0.00 |
0.00 |
1,115,092.44 |
|
22. |
|
|
32 Lease Contracts Receivable |
Current |
1,185,523.20 |
0.00 |
0.00 |
1,185,523.20 |
|
23. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
256,767.77 |
0.00 |
256,767.77 |
0.00 |
|
24. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
255,835.13 |
0.00 |
255,835.13 |
0.00 |
|
25. |
REM - Not Insured by HFC |
|
Bills Purchased - Documentary |
Current |
644,458.82 |
0.00 |
644,458.82 |
0.00 |
|
26. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
1,400,296.95 |
0.00 |
1,400,296.95 |
0.00 |
|
27. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
5,580,463.35 |
0.00 |
5,580,463.35 |
0.00 |
|
28. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
5,133,150.00 |
0.00 |
5,133,150.00 |
0.00 |
|
29. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
5,001,497.33 |
0.00 |
5,001,497.33 |
0.00 |
|
30. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
2,340,508.91 |
0.00 |
2,340,508.91 |
0.00 |
|
31. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
231,566.86 |
0.00 |
231,566.86 |
0.00 |
|
32. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
1,008,420.00 |
0.00 |
1,008,420.00 |
0.00 |
|
33. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
266,885.49 |
0.00 |
266,885.49 |
0.00 |
|
34. |
REM - Not Insured by HFC |
|
Import Bills |
Current |
799,654.00 |
0.00 |
799,654.00 |
0.00 |
|
35. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
576,685.79 |
0.00 |
576,685.79 |
0.00 |
|
36. |
REM - Not Insured by HFC |
|
Bills Purchased - Documentary |
Current |
507,441.05 |
0.00 |
507,441.05 |
0.00 |
|
37. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
494,449.90 |
0.00 |
494,449.90 |
0.00 |
|
38. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
377,908.86 |
0.00 |
377,908.86 |
0.00 |
|
39. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
358,364.83 |
0.00 |
358,364.83 |
0.00 |
|
40. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
5,194,885.92 |
0.00 |
5,194,885.92 |
0.00 |
|
41. |
REM - Not Insured by HFC |
|
Import Bills Under Trust Receipts (TR) |
Current |
969,216.60 |
0.00 |
969,216.60 |
0.00 |
|
42. |
|
|
Customers Liability for this Banks Acceptances Outstanding |
Current |
359,187.50 |
0.00 |
0.00 |
359,187.50 |
|
43. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
77,853.95 |
0.00 |
0.00 |
77,853.95 |
|
44. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
127,234.80 |
0.00 |
0.00 |
127,234.80 |
|
45. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
138,461.40 |
0.00 |
0.00 |
138,461.40 |
|
46. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
167,738.54 |
0.00 |
0.00 |
167,738.54 |
|
47. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
271,496.43 |
0.00 |
0.00 |
271,496.43 |
|
48. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
290,570.00 |
0.00 |
0.00 |
290,570.00 |
|
49. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
354,016.88 |
0.00 |
0.00 |
354,016.88 |
|
50. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
2,013,375.00 |
0.00 |
0.00 |
2,013,375.00 |
|
51. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
413,153.40 |
0.00 |
0.00 |
413,153.40 |
|
52. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
479,597.56 |
0.00 |
0.00 |
479,597.56 |
|
53. |
|
|
Customers Liability for this Banks Acceptances Outstanding |
Current |
524,057.44 |
0.00 |
0.00 |
524,057.44 |
|
54. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
673,790.24 |
0.00 |
0.00 |
673,790.24 |
|
55. |
|
|
Customers Liability for this Banks Acceptances Outstanding |
Current |
715,091.00 |
0.00 |
0.00 |
715,091.00 |
|
56. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
1,339,758.82 |
0.00 |
0.00 |
1,339,758.82 |
|
57. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
14,515,565.60 |
0.00 |
0.00 |
14,515,565.60 |
|
58. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
8,776,483.92 |
0.00 |
0.00 |
8,776,483.92 |
|
59. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
3,878,595.60 |
0.00 |
0.00 |
3,878,595.60 |
|
60. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
3,721,423.50 |
0.00 |
0.00 |
3,721,423.50 |
|
61. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
322,047.90 |
0.00 |
0.00 |
322,047.90 |
|
62. |
Chattel Mortgage |
|
Mortgage Contract Receivable |
Current |
2,535,151.00 |
0.00 |
2,535,151.00 |
0.00 |
|
63. |
|
|
Import Bills Under Trust Receipts (TR) |
Current |
1,430,694.72 |
0.00 |
0.00 |
1,430,694.72 |
|
64. |
REM - Not Insured by HFC |
BIRON HERNAN D AND BIRON FERJENEL G |
Import Bills Under Trust Receipts (TR) |
Current |
1,956,873.60 |
0.00 |
1,956,873.60 |
0.00 |
|
65. |
REM - Not Insured by HFC |
BIRON HERNAN D AND BIRON FERJENEL G |
Import Bills Under Trust Receipts (TR) |
Current |
1,905,417.60 |
0.00 |
1,874,491.98 |
30,925.62 |
|
66. |
REM - Not Insured by HFC |
BIRON HERNAN D AND BIRON FERJENEL G |
Import Bills |
Current |
303,770.00 |
0.00 |
303,770.00 |
0.00 |
|
67. |
REM - Not Insured by HFC |
BIRON HERNAN D AND BIRON FERJENEL G |
Import Bills Under Trust Receipts (TR) |
Current |
1,967,055.60 |
0.00 |
1,967,055.60 |
0.00 |
|
68. |
REM - Not Insured by HFC |
BIRON HERNAN D AND BIRON FERJENEL G |
Import Bills |
Current |
3,988,348.22 |
0.00 |
3,988,348.22 |
0.00 |
|
69. |
REM - Not Insured by HFC |
BIRON HERNAN D AND BIRON FERJENEL G |
Import Bills Under Trust Receipts (TR) |
Current |
90,261.60 |
0.00 |
90,261.60 |
0.00 |
Letters of Credit/Guarantee
This section contains credit exposure records of one million and above
transactions reported quarterly by banks and other financial institutions. For
quarter ending as of December 31, 2012
Subject: PHILIPPINE PHARMAWEALTH INC
|
NO |
Collateral/Security |
Co Maker's Name |
Loan Type |
Loan Status |
Outstanding Amount |
Market Gain/Loss |
|
1. |
246,300.00 |
246,300.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
2. |
751,830.75 |
751,830.75 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
3. |
92,100.00 |
92,100.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
4. |
985,200.00 |
6,305.28 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
5. |
597,600.00 |
597,600.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
6. |
35,000.00 |
35,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
7. |
352,000.00 |
352,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
8. |
1,500,000.00 |
1,500,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
9. |
63,000.00 |
63,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
10. |
29,499.20 |
29,499.20 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
11. |
499,000.00 |
499,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
12. |
880,000.00 |
880,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
13. |
299,000.00 |
299,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
14. |
24,000.00 |
24,000.00 |
|
|
LETTERS OF CREDIT Stand-by Letters of Credit |
0.00 |
|
15. |
480,285.00 |
480,285.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
16. |
4,997,888.79 |
38,743.74 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
17. |
2,924,350.00 |
2,924,350.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
18. |
2,375,267.50 |
2,375,267.50 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
19. |
981,600.00 |
981,600.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
20. |
382,730.67 |
19,840.59 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
21. |
529,590.60 |
12,883.50 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
22. |
1,431,711.23 |
3,047.04 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
23. |
1,227,000.00 |
1,227,000.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
24. |
23,370,175.50 |
7,700,980.00 |
REM Insured by Home Financing Commission (HFC) |
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
25. |
7,203,864.24 |
7,203,864.24 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
26. |
3,973,774.47 |
3,973,774.47 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
27. |
1,380,375.00 |
1,380,375.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
28. |
1,022,500.00 |
1,022,500.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
29. |
667,488.00 |
667,488.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
30. |
302,660.00 |
302,660.00 |
|
|
LETTERS OF CREDIT Regular Letters of Credit |
0.00 |
|
31. |
302,660.00 |
302,660.00 |
|
|
GUARANTEES ISSUED Shipside Bonds Guarantees Issued |
0.00 |
NEGATIVE RECORDS
COURT CASES RESULTS
PHILIPPINE PHARMAWEALTH INC
Case Number : 04 754
Courts : REGIONAL
TRIAL COURT
Branch : 138
Case Type :
INFRINGEMENT
Plaintiff Name : PFIZER INC
Action :
UNAVAILABLE
Date Filed :
Action Date : NA
City : MAKATI
CITY
PHILIPPINE PHARMAWEALTH INC ET AL
Case Number : 05-1047
Courts : REGIONAL
TRIAL COURT
Branch : 134
Case Type : CONTEMPT
Plaintiff Name : PFIZER INC
Action :
UNAVAILABLE
Date Filed :
City : MAKATI
CITY
Above information were based on the subjects 2012
General Information Sheet, the latest available at the Securities and Exchange
Commission and available databases.
Address verification per interview with Ms. Ronya
De Recto, Sales Staff.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.91 |
|
|
1 |
Rs.84.44 |
|
Euro |
1 |
Rs.71.31 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SCs credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.